RT Journal Article
SR Electronic
T1 Impaired Proactive Cognitive Control in Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.14.23288567
DO 10.1101/2023.04.14.23288567
A1 Kricheldorff, Julius
A1 Ficke, Julia
A1 Debener, Stefan
A1 Witt, Karsten
YR 2023
UL http://medrxiv.org/content/early/2023/04/17/2023.04.14.23288567.abstract
AB Adaptive control has been studied in Parkinson’s disease (PD) mainly in the context of proactive control and with mixed results. We compared reactive- and proactive control in 30 participants with Parkinson’s disease (PD) to 30 age matched healthy control participants (HC). The electroencephalographic (EEG) activity of the participants was recorded over 128 channels while they performed a numerical Stroop task, in which we controlled for confounding stimulus-response learning. We assessed effects of reactive- and proactive control on reaction time-, accuracy- and EEG time-frequency data. Behavioral results show distinct impairments of proactive-reactive control in participants with PD, when tested on their usual medication. Participants with PD were unable to adapt cognitive control proactively and were less effective to resolve conflict using reactive control. Successful reactive and proactive control in the HC group was accompanied by a reduced conflict effect between congruent and incongruent items in midline-frontal theta power. Our findings provide evidence for a general impairment of proactive control in PD and suggest that the same may be the case for reactive control.Competing Interest StatementThe authors declare no conflict of interest associated with the present study. Outside the present study we report that K. W. receives research support for the German Research Foundation (DFG GK 2783) and from STADAPHARM. He serves as a consultant for BIAL and receives speaker's honoraria from BIAL, STADAPHARM and Boston Scientific.Clinical TrialDRKS00023020Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The medical ethics committee of the Carl von Ossietzky University of Oldenburg gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDue to privacy concerns the data cannot be made publicly available. The experiment, and code used for the analysis and experiment can be found at: https://osf.io/bsn8v/